EGFR and non-small cell lung carcinoma: The discovery of oncogenic driver mutations, including epidermal growth factor receptor (EGFR) mutations, has dramatically changed our practical strategy for patients with advanced non‐small‐cell lung cancer (NSCLC; Saito et al., 2016).